98%
921
2 minutes
20
Background: The effect of valvulopathy on adverse in-hospital outcomes after partial nephrectomy (PN) and radical nephrectomy (RN) is unknown.
Patients And Methods: Descriptive analyses, 1:2 propensity score matching and multivariable logistic and Poisson regression models were used to address National Inpatient Sample (2000-2019) patients with kidney cancer who underwent PN and RN, stratified according to presence or absence of valvulopathy.
Results: Overall, 38,673 patients underwent PN versus 92,072 RN. Of those, 836 (2.2%) and 2651 (2.9%) had valvulopathy, respectively. Valvulopathy rate decreased from 3.04 to 1.57% in PN patients (2000-2019, EAPC: -1.74%, p = 0.02), and from 2.97 to 2.28% in RN patients (2000-2019, EAPC: -0.94%, p = 0.01). RN patients with valvulopathy were older and carried a higher number of comorbidities than PN patients with valvulopathy. Valvulopathy in PN patients independently predicted higher rates of adverse in-hospital outcomes in 7 of 14 examined categories, with odds ratio (OR) ranging from 2.96 for cardiac complications to 2.35 for vascular complications and 1.78 for bleeding complications (all p < 0.05), but not in-hospital mortality (p > 0.05). Valvulopathy in RN patients independently predicted higher rates of adverse in-hospital outcomes in 9 of 14 examined categories, with OR ranging from 2.88 for cardiac complications to 1.83 for vascular complications and 1.43 for overall complications (all p < 0.05), but not in-hospital mortality (p > 0.05).
Conclusions: Patients with valvulopathy treated with RN are generally older and present with more baseline comorbidities. In this population, RN is associated with a higher risk of adverse in-hospital outcomes compared with PN when examining the impact of valvulopathy on such outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1245/s10434-025-17769-w | DOI Listing |
Jpn J Clin Oncol
September 2025
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Background: Amrubicin monotherapy has been used in Japan for patients with refractory, relapsed, small cell lung cancer (SCLC). However, the clinical guidelines do not specify a recommended initial dose for elderly patients. This retrospective study aimed to explore the appropriate initial dose of amrubicin for elderly patients with refractory, relapsed SCLC.
View Article and Find Full Text PDFAm J Case Rep
September 2025
Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
BACKGROUND Periprosthetic tibial fractures following total knee arthroplasty (TKA) are increasingly encountered in very elderly patients, where multiple comorbidities and osteoporosis compromise early mobilization and elevate the risk of complications. Maintaining pre-injury activities of daily living (ADL) while ensuring safe surgical management is challenging. We present a case of a 95-year-old woman with a periprosthetic tibial shaft fracture managed with open reduction, additional plate fixation, and Ilizarov external fixation, enabling immediate postoperative weight-bearing.
View Article and Find Full Text PDFJ Invest Dermatol
September 2025
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Inflamm Bowel Dis
September 2025
IBD Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy.
Background: The infliximab (IFX) biosimilar, CT-P13, is available as an intravenous (IV) and subcutaneous (SC) formulation. Although current indications allow the transition from IV CT-P13 to SC CT-P13 after two IV administrations, some clinicians prefer to postpone switching until stable clinical remission has been achieved.
Methods: We evaluate the endoscopic response, treatment persistence, clinical remission, endoscopic remission, and safety profile after one year of treatment with IFX in patients switched from IV to SC after 6 weeks (early switch group) or after 6 months (late switch group).
Aust N Z J Psychiatry
September 2025
Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, Melbourne, VIC, Australia.
Psychotropic pharmacogenetics (PGx) offers significant potential advancements in psychiatric care by optimising medication selection and dosing based on genetic factors. This perspective article highlights the clinical utility, health economic implications and implementation challenges of psychotropic PGx, proposing that its broader implementation could enhance patient outcomes and reduce healthcare costs. Landmark studies show that PGx-guided care results in fewer adverse drug reactions and improved medication efficacy, with substantial cost savings compared to traditional prescribing methods.
View Article and Find Full Text PDF